Home/Filings/4/0001567619-18-002232
4//SEC Filing

RAY DEBANJAN 4

Accession 0001567619-18-002232

CIK 0001501989other

Filed

Sep 5, 8:00 PM ET

Accepted

Sep 6, 7:18 PM ET

Size

8.3 KB

Accession

0001567619-18-002232

Insider Transaction Report

Form 4
Period: 2018-09-04
RAY DEBANJAN
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-09-04+3,00016,220 total
    Exercise: $1.45Exp: 2024-02-27Common Stock (3,000 underlying)
  • Exercise/Conversion

    Common Stock

    2018-09-04$1.45/sh+3,000$4,3478,928 total
  • Sale

    Common Stock

    2018-09-04$22.39/sh3,000$67,1705,928 total
Footnotes (2)
  • [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  • [F2]100% of the shares subject to the option are fully vested and exercisable.

Documents

1 file

Issuer

CytomX Therapeutics, Inc.

CIK 0001501989

Entity typeother

Related Parties

1
  • filerCIK 0001706863

Filing Metadata

Form type
4
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 7:18 PM ET
Size
8.3 KB